Drug Approval | February 24, 2023
SERDA therapeutics submits IND for wound debridement agent
Clinical studies are expected to start in Q2 2023.
Clinical studies are expected to start in Q2 2023.
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
The new sterile filling line meets cGMP aseptic filling regulatory requirements
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
Agasta Software is engaged in research, development and commercialization of medical devices
Subscribe To Our Newsletter & Stay Updated
